ArticleJournal of the American Board of Family Medicine : JABFM
Buprenorphine Prescribing Among Primary Care Clinicians for Chronic Pain and Opioid Use Disorder.
Article in Journal of the American Board of Family Medicine : JABFM. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of Loma Linda University Health clinicians' beliefs, knowledge and experiences regarding pain management.BMC health services research · 2026Article
- Women's Health, Social Issues, and Quality of Care in Family Medicine.Journal of the American Board of Family Medicine : JABFMArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBuprenorphine is a partial µ-opioid agonist approved by the Food and Drug Administration (FDA) for the treatment of chronic pain and opioid use disorder (OUD). Despite its favorable safety profile compared with other opioids and the 2022 US Department of Veterans Affairs and Department of Defense guideline recommending it as first-line opioid for patients with chronic pain requiring daily opioids, its adoption among primary care clinicians (PCCs) remains limited. This survey aims to evaluate PCCs' familiarity with and interest in prescribing and/or transitioning patients to buprenorphine for chronic pain and OUD. In addition, we assessed their interest in using an electronic Consult (eConsult) platform to support buprenorphine prescribing.
methodsAn anonymized electronic survey was distributed to our institution's PCCs working across 53 clinics in rural southern Minnesota and western Wisconsin. Our survey was deployed for 2 weeks. We received 146 responses (31.7% response rate).
resultsOnly 37% of respondents currently prescribe buprenorphine, and 19% prescribed it for both OUD and chronic pain. Despite this, 72% expressed interest in prescribing buprenorphine in the future. Key barriers to prescribing included insufficient knowledge (76%) and lack of confidence (78%). Additional concerns included cost, insurance challenges, stigma, patient resistance, and inadequate training. Notably, 89% of respondents expressed interest in using an eConsult platform for buprenorphine initiation and transition.
conclusionThese findings suggest a need for enhanced education, resource access, and institutional support to help PCCs incorporate buprenorphine into their practices, potentially improving the management of chronic pain and OUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.